Does the Modification of Starting Gonadotropin Dose During Intracytoplasmic Sperm Injection Cycle Have Any Significant Impact on Cycle Outcome?

Clinical pregnancy rates were similar between groups.CONCLUSION: Dose alteration requirement along intracytoplasmic sperm injection cycle result in highnumber of total and metaphase 1 oocyte yields, higher starting gonadotropin and total gonadotropindose, duration of stimulation and estradiol level at trigger day, however clinical pregnancy rates weresimilar between groups.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:OBJECTIVE: The aim of this study was to figure out the impact of gonadotropin dose alteration requirements due to high response or unresponsiveness on intracytoplasmic sperm injection cycle outcomes in a standard group of patients.STUDY DESIGN: One hundred cycles with same gonadotropin dosage along the stimulation were compared with 100 cycles in which gonadotropin dose alterations were needed due to high response or unresponsiveness.

📊

Key Findings & Data:Groups were compared in terms of age, body mass index, serum follicle stimulatinghormone and estradiol levels, antral follicle count, gonadotropin dosage, duration of stimulation, endometrial thickness at trigger day, number of total, mature and immature oocytes and finally the clinicalpregnancy rates.

💡

Conclusion & Impact:Clinical pregnancy rates were similar between groups.CONCLUSION: Dose alteration requirement along intracytoplasmic sperm injection cycle result in highnumber of total and metaphase 1 oocyte yields, higher starting gonadotropin and total gonadotropindose, duration of stimulation and estradiol level at trigger day, however clinical pregnancy rates weresimilar between groups.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: The aim of this study was to figure out the impact of gonadotropin dose alteration requirements due to high response or unresponsiveness on intracytoplasmic sperm injection cycle outcomes in a standard group of patients.STUDY DESIGN: One hundred cycles with same gonadotropin dosage along the stimulation were compared with 100 cycles in which gonadotropin dose alterations were needed due to high response or unresponsiveness. Groups were compared in terms of age, body mass index, serum follicle stimulatinghormone and estradiol levels, antral follicle count, gonadotropin dosage, duration of stimulation, endometrial thickness at trigger day, number of total, mature and immature oocytes and finally the clinicalpregnancy rates. RESULTS: There were significant differences between groups with regard to gonadotropin startingdose, total gonadotropin dose, duration of stimulation, estradiol level at trigger day, number of totaloocytes and metaphase 1 oocyte number. Clinical pregnancy rates were similar between groups.CONCLUSION: Dose alteration requirement along intracytoplasmic sperm injection cycle result in highnumber of total and metaphase 1 oocyte yields, higher starting gonadotropin and total gonadotropindose, duration of stimulation and estradiol level at trigger day, however clinical pregnancy rates weresimilar between groups.

🔖

Cite This Article

ÖZKAYA, E., ŞAHİN, Y., ESER, S. K., ALBAYRAK, B., BULDUK, O., ŞANVERDİ, İ., KUTLU, T. (2017). Does the Modification of Starting Gonadotropin Dose During Intracytoplasmic Sperm Injection Cycle Have Any Significant Impact on Cycle Outcome?. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 23 - Sayı: 3, 138–142. https://ajindex.com/articles/226987

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (12)

Evian Annual Reproduction Workshop Group 2007, Fauser BC, Diedrich K, Devroey P. Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum Reprod Update 2008 Jan-Feb;14(1):1-14
Alviggi C, Humaidan P, Ezcurra D. Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols. Reprod Biol Endocrinol 2012 Feb 6;10:9
Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF/ICSI outcome. Hum Reprod Update 2006 Nov-Dec;12(6):685-718
La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010 Mar-Apr;16(2):113-30
Nelson SM, Yates RW, Fleming R. Serum anti-Mu?llerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles- implications for individualization of therapy. Hum Reprod 2007 Sep;22(9):2414-21
Nelson SM, Yates RW, Lyall H, Jamieson M, Traynor I, Gaudoin M et al. Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009 Apr;24(4):867-75
Yates AP, Rustamov O, Roberts SA, Lim HY, Pemberton PW, Smith A et al Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF/ICSI. Hum Reprod 2011 Sep;26(9):2353-62
Pouly JL, Olivennes F, Massin N, Celle M, Caizergues N, Contard F. Usability and utility of the CONSORT calculator for FSH starting doses: a prospective observational study. Reprod Biomed Online 2015 Sep;31(3):347-55
La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF/ICSI using ovarian reserve markers: from theory to practice. Hum Reprod Update 2014 Jan-Feb;20(1):124-40
Broer SL, van Disseldorp J, Broeze KA, Dolleman M, Opmeer BC, Bossuyt P et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update 2013 JanFeb;19(1):26-36
Seifer DB, Maclaughlin DT. Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance. Fertil Steril 2007 Sep;88(3):539-46
Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and I